our mission
Pioneering a new class of treatments for neuro-visual disorders.
Around 15 million Americans suffer from vision loss caused by deficiencies in the brain, instead of any structural issues with the eyes. Traditional therapeutic modalities are unable to properly target and treat these deficits, leaving a significant unmet need.
By harnessing the latest in digital technology, we're creating an
entirely new category of medicines to address these conditions. We
develop software products that generate therapeutic visual stimuli and
deliver them to the patient through a virtual reality headset, using the
eyes to stimulate the brain. The success of our amblyopia therapeutic
provides proof-of-concept for our broader platform.
Development Pipeline
In The News
'Lazy eye' in kids is an age-old problem: A new VR headset brought treatment into the 21st century
November 23, 2021
FDA approves Luminopia's VR-based digital therapeutic which treats lazy eye with TV time
October 21, 2021
press releases
Follow along with our latest news.
For press inquiries, please contact pr@luminopia.com.
Luminopia Announces FDA Approval of Digital Therapeutic that Uses TV Shows to Improve Vision in Children with Lazy Eye
October 20, 2021
Luminopia One, a Digital Therapeutic for Amblyopia, Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial
September 14, 2021
Leadership Team
To achieve our mission, we've brought together a world-class team with deep experience and a true passion for helping patients.
Brion Raymond
CBO
Former CCO at Clearside Biomedical
Former Director at Genentech
Endri Angjeli
VP of Clinical Development
Former Director at Ora
Biomedical Engineer
Hank Wu
COO
Former VP of Digital at Evelo Biosciences
Former Director at Biogen
Katrina Moseley Journey
VP of Commercial
Former GM of Dompe Canada
Former Sr. Director Clearside Biomedical and Santen
Scott Xiao
Co-Founder and CEO
MIT TR Innovators Under 35
Forbes 30 Under 30
Sunny Atwal
VP of Engineering
Former VP of Technology at Moth+Flame Former SVP of Technology at Littlstar
board of directors
We're proud to have the support of an exceptional Board of Directors, with leaders from across healthcare, tech, and entertainment.
Casey Tansey
General Partner at USVP
Former CEO at Epicor Medical, Heartport
Dean Travers
Co-Founder
Thiel Fellow
Forbes 30 Under 30
Mark Jacobstein
Executive Business Advisor at Immunai Former CUEO at Guardant Health
Robert Langer, ScD
Institute Professor at MIT; Co-Founder of Moderna; Most cited engineer in history
Scott Xiao
CEO
MIT TR Innovators Under 35
Forbes 30 Under 30
William Dai
Founding Managing Partner at ShangBay Capital; Former CFO at Boston Scientific China
Investors
We're grateful to have the backing of several top-tier investment firms who share our vision for the future.
Platform scientific advisors
We're thrilled to have a group of renowned clinicians and scientists guiding the development of our platform.
Peter J. McDonnell, MD
Director, Professor of Ophthalmology
The Wilmer Eye Institute
Marguerite McDonald, MD, FACS
Clinical Professor of Ophthalmology
New York University Langone Medical Center
Peter Bex, PhD
Chair of Psychology
Northeastern University
Krystel Huxlin, PhD
Professor of Ophthalmology
University of Rochester
Eric Singman, MD
Professor of Ophthalmology
University of Maryland
Indications, Safety and Warnings
Indications:
Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. Luminopia is indicated for improvement in visual acuity in amblyopia patients, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care professional. Luminopia is intended for both previously treated and untreated patients; however, patients with more than 12 months of prior treatment (other than refractive correction) have not been studied. Luminopia is intended to be used as an adjunct to full-time refractive correction, such as glasses, which should also be worn under the HMD during Luminopia therapy. Luminopia is intended for Prescription Use Only, in an at-home environment.
Safety:
In the Luminopia pivotal trial, 14 patients (25%) experienced adverse events in the treatment group vs. 8 (14%) in the control group. Ocular AEs were reported in 6 (11%) patients in the treatment group and 8 (14%) patients in the control. No serious adverse events (AEs) were reported. The most frequent non-serious AE potentially related to Luminopia was headache (14.3%), for which all cases were graded as mild, transient, and resolved without sequelae.
Warnings:
Rx only: Federal law restricts this device on the order of a trained eye-care professional.
Safety and effectiveness of Luminopia beyond 12 weeks is unknown. The long-term effects of HMD use in patients 4-7 years of age are unknown. Patients with a history of light-induced seizures, or serious medical conditions, should contact a doctor before using Luminopia. Patients should only use Luminopia while wearing their prescribed glasses under the HMD. Patients should stop using Luminopia and contact a doctor if they experience a new or worsened eye-turn, or double vision. Patients with an interpupillary distance of less than 52 mm should not use Luminopia.
Copyright 2023 © Luminopia, Inc. All rights reserved.